{
    "eid": "2-s2.0-85029227305",
    "title": "Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial",
    "cover-date": "2017-11-01",
    "subject-areas": [
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        },
        {
            "$": "Immunology",
            "@code": "2403"
        },
        {
            "$": "Epidemiology",
            "@code": "2713"
        },
        {
            "$": "Virology",
            "@code": "2406"
        }
    ],
    "keywords": [],
    "authors": [
        "Pedro Cahn"
    ],
    "citedby-count": 36,
    "ref-count": 27,
    "ref-list": [
        "Antiretroviral drugs for treatment and prevention of HIV infection in Adults: 2016 recommendations of the international antiviral society-USA Panel",
        "Raltegravir as antiretroviral therapy in HIV/AIDS",
        "Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: Evidence-based recommendations from an international association of physicians in AIDS care panel",
        "Better adherence with once-daily antiretroviral regimens: A meta-analysis",
        "Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz",
        "The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: The NOCTE study",
        "Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-na\u00efve HIV-1-infected patients over 96 weeks",
        "Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 non-inferiority trial",
        "Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-na\u00efve HIV-infected patients",
        "Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir",
        "Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non\u2010zero risk difference or non\u2010unity relative risk",
        "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks",
        "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial",
        "Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 infection",
        "Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study",
        "Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study",
        "Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial",
        "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-na\u00efve volunteers infected with HIV-1: A Randomized, controlled equivalence trial",
        "Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study",
        "Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection",
        "Influence of sex/gender and race on responses to raltegravir combined with tenofovir-emtricitabine in treatment-naive human immunodeficiency virus-1 infected patients: Pooled analyses of the STARTMRK and QDMRK studies",
        "Review of the efficacy, safety, and pharmacokinetics of raltegravir in pregnancy"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Cape Town",
            "affilname": "Desmond Tutu Health Foundation",
            "affiliation-country": "South Africa"
        },
        {
            "affiliation-city": "Paris",
            "affilname": "Universit\u00e9 Paris Cit\u00e9",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Johannesburg",
            "affilname": "Helen Joseph Hospital",
            "affiliation-country": "South Africa"
        },
        {
            "affiliation-city": "Buenos Aires",
            "affilname": "Fundacion Huesped",
            "affiliation-country": "Argentina"
        },
        {
            "affiliation-city": "Paris",
            "affilname": "H\u00f4pital Bichat-Claude-Bernard AP-HP",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Paris",
            "affilname": "H\u00f4pital Universitaire Piti\u00e9 Salp\u00eatri\u00e8re",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Philadelphia",
            "affilname": "Thomas Jefferson University",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Rahway",
            "affilname": "Merck &amp; Co., Inc.",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "affilname": "Harvard Medical School",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Ghent",
            "affilname": "Universiteit Ghent, Faculteit Geneeskunde en Gezondheidswetenschappen",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Guatemala City",
            "affilname": "Edifico Galer\u00edas",
            "affiliation-country": "Guatemala"
        },
        {
            "affiliation-city": "Sydney",
            "affilname": "Holdsworth House Medical Practice",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Los Angeles",
            "affilname": "Ruane Medical and Liver Health Institute",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Gilead stockholder",
        "Merck",
        "Gilead Sciences",
        "Janssen Biotech",
        "AbbVie",
        "ViiV Healthcare"
    ]
}